Author:
Alaei Samaneh,Wang Yamin,Liu Yueli,Schiele Julia,Deng Rong,Shiller Danielle,Marroum Patrick,Menon Rajeev,Salem Ahmed Hamed
Reference40 articles.
1. Venclexta (venetoclax) [package insert]. North Chicago, IL; AbbVie, Inc.; 2016. Revised 6/2022.
2. Bioavailability evaluation of venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100 mg tablet;Badawi;Clin Drug Investig,2022
3. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets;Souers;Nat Med,2013
4. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma;Salem;J Clin Pharmacol,2017
5. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia;Salem;Anticancer Drugs,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献